Guardant Health's (GH) Neutral Rating Reaffirmed at Guggenheim

Guardant Health (NASDAQ:GH - Get Free Report)'s stock had its "neutral" rating reissued by equities research analysts at Guggenheim in a research report issued on Friday, Benzinga reports.

Several other research analysts also recently issued reports on GH. Wolfe Research started coverage on shares of Guardant Health in a research report on Wednesday, December 13th. They set a "peer perform" rating on the stock. Piper Sandler lowered their price objective on shares of Guardant Health from $40.00 to $30.00 and set an "overweight" rating on the stock in a research report on Monday, February 26th. The Goldman Sachs Group lowered their price objective on shares of Guardant Health from $43.00 to $37.00 and set a "buy" rating on the stock in a research report on Monday, January 29th. JPMorgan Chase & Co. lowered their price objective on shares of Guardant Health from $60.00 to $45.00 and set an "overweight" rating on the stock in a research report on Friday, February 23rd. Finally, Canaccord Genuity Group lowered their price objective on shares of Guardant Health from $50.00 to $45.00 and set a "buy" rating on the stock in a research report on Friday, February 23rd. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, Guardant Health has an average rating of "Moderate Buy" and a consensus price target of $41.30.

Guardant Health Stock Down 2.9 %

Shares of NASDAQ:GH traded down $0.52 during trading hours on Friday, reaching $17.63. The stock had a trading volume of 2,482,747 shares, compared to its average volume of 1,907,301. The company has a debt-to-equity ratio of 7.18, a quick ratio of 6.24 and a current ratio of 6.54. The firm's 50 day moving average is $20.15 and its 200-day moving average is $23.95. The stock has a market capitalization of $2.15 billion, a price-to-earnings ratio of -4.12 and a beta of 0.87. Guardant Health has a 1 year low of $16.92 and a 1 year high of $41.06.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Thursday, February 22nd. The company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($0.93) by ($0.65). The company had revenue of $155.05 million during the quarter, compared to analysts' expectations of $151.71 million. Guardant Health had a negative net margin of 85.02% and a negative return on equity of 301.94%. Research analysts predict that Guardant Health will post -3.49 earnings per share for the current fiscal year.

Insider Transactions at Guardant Health

In related news, insider Kumud Kalia acquired 2,187 shares of Guardant Health stock in a transaction that occurred on Monday, March 18th. The stock was purchased at an average price of $17.82 per share, for a total transaction of $38,972.34. Following the completion of the purchase, the insider now directly owns 12,722 shares of the company's stock, valued at $226,706.04. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 6.20% of the company's stock.

Hedge Funds Weigh In On Guardant Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in Guardant Health by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 11,130,654 shares of the company's stock worth $301,084,000 after acquiring an additional 180,424 shares during the last quarter. Wellington Management Group LLP raised its position in Guardant Health by 24.1% during the fourth quarter. Wellington Management Group LLP now owns 834,084 shares of the company's stock worth $22,562,000 after acquiring an additional 161,986 shares during the last quarter. Virtu Financial LLC acquired a new position in Guardant Health during the fourth quarter worth about $233,000. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Guardant Health during the fourth quarter worth about $3,868,000. Finally, Eventide Asset Management LLC grew its holdings in shares of Guardant Health by 8.3% during the fourth quarter. Eventide Asset Management LLC now owns 3,888,146 shares of the company's stock worth $105,174,000 after buying an additional 298,616 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.